Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Curasan AG    CURG   DE0005494538

CURASAN AG

(CURG)
SummaryNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

curasan : takes over dental company with innovative technology

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/03/2019 | 02:47pm EDT
  • Company acquisition successfully completed
  • Minimal-invasive treatment system for implantologists
  • Ideal expansion of curasan product range as solution provider

Kleinostheim, 3 July 2019 - curasan AG, Germany, (ISIN old: DE0005494538 / new since 3 July 2019: DE000A2YPGM4), a leading specialist for medical products in the field of orthobiologics, has now successfully completed the acquisition of a dental company announced at the end of January as part of its strategic realignment. The parties have agreed confidentiality on the purchase price.

The acquired company is JEDER GmbH, Dental Technology, Klosterneuburg/Vienna, Austria, which developed the innovative JEDER-system for implantologists.

With the help of the JEDER-system, a sinus lift in the upper jaw - otherwise a 'dreaded' surgery - can be performed in an easy and almost painless manner. The procedure is completely minimally invasive for patients, without incision or suture.This gives the JEDER-system a convincing unique selling point in the market.

'The JEDER-System is a surgical device with economically attractive disposables - an ideal complement to our product range for dental implantology', explains Michael Schlenk, CEO of curasan AG. 'This will result in interesting cross-selling possibilities regarding our CERASORB Paste, which is perfectly suited for the combined use with the JEDER-system. '

'The treatment method associated with the JEDER-system is regarded by experts as a future global standard procedure for the minimal-invasive sinus lift,' outlines Gregor Siebert, Head of Marketing and Sales at curasan AG.

'The technology has great future potential; it opens new markets for us and is a helpful door-opener at doctors and clinics we did not serve up to now. Furthermore, the simplicity of use offers also less experienced dentists access to this group of patients.'

The product package consists of a bone drill, pump and tubeset and has a CE-certification. Thus, it can be marketed in Europe straightaway. It is also listed in the US. Moreover, there is patent protection for various components in China, India and other countries.

Contact curasan AG:
Andrea Weidner
Investor Relations &
Corporate Communications
+49 6027 40 900-51
ir@curasan.com

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan´s innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.

Disclaimer

curasan AG published this content on 03 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 July 2019 18:47:04 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CURASAN AG
03:23aCURASAN : still on track despite of weaker second quarter
PU
01:55aCURASAN : still on track despite of weaker second quarter
EQ
07/03CURASAN : takes over dental company with innovative technology
PU
More news
Chart CURASAN AG
Duration : Period :
curasan AG Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Michael Schlenk Chief Executive Officer
Detlef Wilke Chairman-Supervisory Board
Christine Uekert Chief Financial Officer
Fabian Peters Technical Director
Dirk Honold Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CURASAN AG11
CSL LIMITED26.62%72 390
BIOGEN INC.-23.14%43 009
ALEXION PHARMACEUTICALS17.95%25 750
GRIFOLS27.07%19 474
SAMSUNG BIOLOGICS CO LTD--.--%15 595